GSTM1 and chronic kidney disease: Together with the results from the phase 1/2 trial, the results of this analysis suggest a new therapeutic approach for treating anemia in patients with CKD.8 Treating inflammation, a significant underlying mechanism of disease in many patients with anemia in CKD, has the potential to increase Hb without the need for ESA or iron therapies.